Novartis AG Gross Profit 2010-2023 | NVS
Novartis AG annual/quarterly gross profit history and growth rate from 2010 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Novartis AG gross profit for the quarter ending December 31, 2023 was $6.341B, a 11.68% increase year-over-year.
- Novartis AG gross profit for the twelve months ending December 31, 2023 was $34.188B, a 7.24% increase year-over-year.
- Novartis AG annual gross profit for 2023 was $34.188B, a 7.24% increase from 2022.
- Novartis AG annual gross profit for 2022 was $31.879B, a 13.86% decline from 2021.
- Novartis AG annual gross profit for 2021 was $37.01B, a 6.42% increase from 2020.
Novartis AG Annual Gross Profit
(Millions of US $) |
| 2023 |
$34,188 |
| 2022 |
$31,879 |
| 2021 |
$37,010 |
| 2020 |
$34,777 |
| 2019 |
$34,252 |
| 2018 |
$31,589 |
| 2017 |
$32,960 |
| 2016 |
$31,916 |
| 2015 |
$32,983 |
| 2014 |
$36,289 |
| 2013 |
$36,137 |
| 2012 |
$36,105 |
| 2011 |
$40,392 |
| 2010 |
$37,073 |
| 2009 |
$32,924 |
Novartis AG Quarterly Gross Profit
(Millions of US $) |
| 2023-12-31 |
$6,341 |
| 2023-09-30 |
$8,975 |
| 2023-06-30 |
$9,595 |
| 2023-03-31 |
$9,277 |
| 2022-12-31 |
$5,678 |
| 2022-09-30 |
$7,909 |
| 2022-06-30 |
$9,334 |
| 2022-03-31 |
$8,958 |
| 2021-12-31 |
$9,546 |
| 2021-09-30 |
$9,429 |
| 2021-06-30 |
$9,380 |
| 2021-03-31 |
$8,655 |
| 2020-12-31 |
$12,566 |
| 2020-09-30 |
$5,032 |
| 2020-06-30 |
$8,193 |
| 2020-03-31 |
$8,986 |
| 2019-12-31 |
$8,724 |
| 2019-09-30 |
$8,706 |
| 2019-06-30 |
$8,618 |
| 2019-03-31 |
$8,204 |
| 2018-12-31 |
$7,859 |
| 2018-09-30 |
$7,923 |
| 2018-06-30 |
$8,095 |
| 2018-03-31 |
$7,712 |
| 2017-12-31 |
$8,675 |
| 2017-09-30 |
$8,369 |
| 2017-06-30 |
$8,236 |
| 2017-03-31 |
$7,680 |
| 2016-12-31 |
$8,117 |
| 2016-09-30 |
$7,973 |
| 2016-06-30 |
$8,228 |
| 2016-03-31 |
$7,598 |
| 2015-12-31 |
$8,255 |
| 2015-09-30 |
$8,097 |
| 2015-06-30 |
$8,409 |
| 2015-03-31 |
$8,222 |
| 2014-12-31 |
$8,938 |
| 2014-09-30 |
$8,879 |
| 2014-06-30 |
$9,571 |
| 2014-03-31 |
$8,901 |
| 2013-12-31 |
$8,564 |
| 2013-09-30 |
$8,780 |
| 2013-06-30 |
$9,193 |
| 2013-03-31 |
$9,600 |
| 2012-12-31 |
$7,281 |
| 2012-09-30 |
$9,464 |
| 2012-06-30 |
$9,931 |
| 2012-03-31 |
$9,429 |
| 2011-12-31 |
$9,878 |
| 2011-09-30 |
$10,246 |
| 2011-06-30 |
$10,504 |
| 2011-03-31 |
$9,764 |
| 2010-12-31 |
$9,940 |
| 2010-09-30 |
$9,158 |
| 2010-06-30 |
$8,715 |
| 2010-03-31 |
$9,260 |
| 2009-12-31 |
$9,478 |
| 2009-09-30 |
$8,187 |
| 2009-06-30 |
$7,918 |
| 2009-03-31 |
$7,341 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$198.840B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
